Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-084858
Filing Date
2025-09-05
Accepted
2025-09-05 12:43:24
Documents
7
Period of Report
2025-09-05

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0256192-6k_purple.htm 6-K 16767
2 FORM OF PRE-FUNDED WARRANT ea025619201ex4-1_purple.htm EX-4.1 103139
3 FORM OF WARRANT ea025619201ex4-2_purple.htm EX-4.2 103232
4 FORM OF PLACEMENT AGENT WARRANT ea025619201ex4-3_purple.htm EX-4.3 104335
5 FORM OF SECURITIES PURCHASE AGREEMENT ea025619201ex10-1_purple.htm EX-10.1 228077
6 PRESS RELEASE: PURPLE BIOTECH ANNOUNCES PRICING OF UP TO $18 MILLION PUBLIC OFFE ea025619201ex99-1_purple.htm EX-99.1 15221
7 GRAPHIC ex99-1_001.jpg GRAPHIC 4461
  Complete submission text file 0001213900-25-084858.txt   578327
Mailing Address 4 OPPENHEIMER STREET SCIENCE PARK REHOVOT L3 7670104
Business Address 4 OPPENHEIMER STREET SCIENCE PARK REHOVOT L3 7670104 97239333121
PURPLE BIOTECH LTD. (Filer) CIK: 0001614744 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37643 | Film No.: 251295812
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)